A medicine used to treat type 2 diabetes has now been approved for use in adults with obstructive sleep apnoea and obesity.

The Therapeutic Goods Administration has approved the first medicine to treat sleep apnoea.

Mounjaro, which has the active ingredient tirzepatide, is widely used to treat type 2 diabetes.

However, the TGA has today expanded the drug’s usage to include obstructive sleep apnoea for adults living with obesity.

A medicine used to treat type 2 diabetes has now been approved for use in adults with obstructive sleep apnoea and obesity.
A medicine used to treat type 2 diabetes has now been approved for use in adults with obstructive sleep apnoea and obesity. (iStock)

This makes Mounjaro the first and only medicine for obstructive sleep apnoea in Australia.

The drug has not been listed on the Pharmaceutical Benefits Scheme and will only be available through private prescription.

Mounjaro can now be used to treat moderate-to-severe obstructive sleep apnoea in adults living with a body mass index (BMI) of 30 or more.

Mounjaro has been approved to treat obesity in Australia.
Mounjaro has been approved to treat sleep apnoea in adults living with obesity. (CNN)

Mounjaro cannot be used to treat type 1 diabetes, or by children and teenagers under 18 years old.

Side effects associated with Mounjaro can include an upset stomach, injection site-related side effects, and low blood sugar. 

Obstructive sleep apnoea is the most common of all sleeping disorders and is thought to affect around 780,000 Australian adults.

It occurs when a person’s upper airway becomes blocked, causing breathing to be repeatedly interrupted during sleep. 

Dr. Brendon Yee, a specialist in respiratory and sleep medicine at the Woolcock Institute of Medical Research, participated in a clinical study on the use of Mounjaro for treating obstructive sleep apnoea.

Yee said the TGA decision was a “long-awaited development” in the field of sleep medicine.

“This marks the first instance where individuals suffering from weight-induced obstructive sleep apnoea can receive a medication that targets the root cause of their disorder,” stated Yee. 

“This marks a significant milestone in the treatment of this debilitating sleep disorder.

“Obstructive sleep apnoea can affect anyone, and obesity is the single greatest cause of the condition.

“At least 70 per cent of people living with obstructive sleep apnoea also live with obesity.”

You May Also Like

Wales sent a message to the rugby world that they are 'still here' after beating New Zealand

Dan Biggar: Wales’ Historic New Zealand Win Must Spark New Era

One of Wales’ most celebrated songs – in rugby and across the…
A revolutionary cancer treatment that can destroy targeted tumour tissue without surgery is attracting international attention and offering new hope to patients who have exhausted conventional options - but it's not yet available in Australia or New Zealand

Australians Pay Fortunes Overseas for Needle-Free Cancer Treatment

A cutting-edge cancer treatment that can destroy tumours without an operation is…